Educational use only. Check doses against the product monograph and local protocols.

proton pump inhibitors

in review 3 min read Updated 2026-10-28
proton pump inhibitors

Irreversible H⁺/K⁺-ATPase inhibitors — the most effective acid suppression. Take 30–60 min before breakfast (before dinner too if BID). Clear indications: erosive oesophagitis, Barrett’s, peptic ulcer and H. pylori therapy, ulcer bleeding, gastroprotection with NSAIDs/antithrombotics in high-risk patients, EoE. Review every long-term prescription — try to stop or step down at least yearly unless Barrett’s, LA grade C/D oesophagitis or prior GI bleeding. Long-term harms are mostly observational; the only one confirmed in an RCT is enteric infection.

mechanism

Prodrugs activated in the acid of the parietal cell canaliculus → bind only active pumps → must be taken before a meal, when pumps are stimulated. Full effect takes 3–5 days.

dosing

indicationregimenduration
uninvestigated GERD (no alarm features)standard dose daily before breakfast8-week trial → then try to stop
erosive oesophagitis LA A/Bstandard dose dailyheal, then step down/on-demand
erosive oesophagitis LA C/D, Barrett’sBID to heal, then lowest effective daily doseindefinite
non-erosive refluxon-demand or intermittent—
refractory symptomsoptimise timing, then BIDobjective testing (gastro-oesophageal reflux disease)
peptic ulcerdailyduration by cause; stop after healing if H. pylori cured and NSAID stopped
H. pylori eradicationBID with antibiotics14 days (peptic ulcer disease and H. pylori)
ulcer bleed, high-risk stigmatahigh-dose IV × 72 h → BID to day 14 → dailyregimen → upper GI bleeding
gastroprotection (prior ulcer bleed on antiplatelet/anticoagulant/NSAID)dailywhile the drug continues
EoEstandard–high dose8 weeks → biopsy (eosinophilic oesophagitis)

Standard daily doses: pantoprazole 40 mg, omeprazole 20 mg, esomeprazole 20–40 mg, lansoprazole 30 mg, rabeprazole 20 mg. Oral is as good as IV whenever the patient can swallow.

key points

  • Deprescribing: no ongoing indication → stop or step down; most GERD patients can try stopping once a year (Choosing Wisely Canada). Taper or switch to on-demand to blunt rebound acid hypersecretion.
  • Clopidogrel: omeprazole and esomeprazole inhibit CYP2C19 → use pantoprazole (antiplatelets).
  • Before H. pylori breath or stool testing: stop PPI 2 weeks (H2RA allowed).
  • No benefit adding a PPI to all inpatients (“stress ulcer prophylaxis”) outside ICU risk criteria.
  • Vonoprazan (potassium-competitive acid blocker) — faster, longer acid suppression, not meal-dependent; used in H. pylori regimens and erosive oesophagitis; limited availability in Canada.

adverse effects

COMPASS (2019): 17 598 patients randomised to pantoprazole vs placebo for ~3 years — no difference in pneumonia, fracture, CKD, dementia, cardiovascular events or death; only enteric infections were higher (1.4% vs 1.0%).

Observational associations (causality unproven; matter in frail or high-risk patients):

  • C. difficile and other enteric infections
  • hypomagnesaemia (→ hypokalaemia, hypocalcaemia) — check Mg²⁺ on long-term use with diuretics
  • B12 and iron malabsorption
  • microscopic colitis (chronic diarrhoea)
  • fractures, pneumonia, acute interstitial nephritis
  • common minor effects: headache, abdominal pain, diarrhoea — try another PPI

ACG 2022 advice to patients: benefits of a PPI for a real indication outweigh these theoretical risks.

Ontario

  • Ontario: ODB lists generic PPIs (some under Limited Use) → LU search.

Prepared 2026-10-28. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction proton pump inhibitors